We found that both of the combination of anti-PD-1 or anti-PD-L1 and ODN1585 impaired tumor growth and reduced tumor burden more effectively than in control mice or mice receiving ODN1585 or anti-PD-1 or anti-PD-L1 antibody alone (Figure S1F-H). This evidence concerns the gene PDCD1 and neoplasm.